

## Meta-analyses

# Cinnamon supplementation positively affects obesity: A systematic review and dose-response meta-analysis of randomized controlled trials



Seyed Mohammad Mousavi <sup>a, b</sup>, Jamal Rahmani <sup>c</sup>, Hamed Kord-Varkaneh <sup>d</sup>, Ali Sheikhi <sup>a</sup>, Bagher Larijani <sup>e</sup>, Ahmad Esmailzadeh <sup>a, f, g, \*</sup>

<sup>a</sup> Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran

<sup>b</sup> Students' Scientific Research Center (SSRC), Tehran University of Medical Sciences (TUMS), Tehran, Iran

<sup>c</sup> Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>d</sup> Student Research Committee, Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>e</sup> Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

<sup>f</sup> Obesity and Eating Habits Research Center, Endocrinology and Metabolism Molecular - Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

<sup>g</sup> Food Security Research Center, Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran

## ARTICLE INFO

## Article history:

Received 2 November 2018

Accepted 9 February 2019

## Keywords:

Cinnamon

Obesity

Weight

Meta-analysis

Dose-response

## SUMMARY

**Background & aims:** Data about the effects of cinnamon supplementation on obesity measures are conflicting. This systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to summarize the effects of cinnamon intake on body weight (BW), Body Mass Index (BMI), Waist Circumference (WC), and fat mass (FM) in adults.

**Methods:** Online electronic search engines including PubMed, SCOPUS, Cochrane Library, and Google Scholar were searched to find pertinent articles until September 2018. Data were pooled using the random-effects method and were expressed as weighted mean difference (WMD) and 95% confidence intervals (CI). The non-linear association was assessed using fractional polynomial modeling.

**Results:** Out of 679 records, 12 trials that enrolled 786 subjects were included. The pooled results showed that cinnamon administration significantly decreased BW (WMD:  $-1.02$  kg, 95% CI:  $-1.66$  to  $-0.38$ ,  $P = 0.002$ ), BMI (WMD:  $-0.51$  kg/m<sup>2</sup>, 95% CI:  $-0.74$ ,  $-0.28$ ,  $P < 0.001$ ), WC (WMD:  $-2.40$  cm, 95% CI:  $-4.48$ ,  $-0.33$ ,  $P = 0.02$ ), and FM (WMD:  $-1.02\%$ , 95% CI:  $-1.80$ ,  $-0.24$ ,  $P = 0.01$ ). Greater effects on BW were observed in subjects aged  $<50$  years old and those with a baseline BMI of  $\geq 30$  kg/m<sup>2</sup>. The cinnamon administrations significantly reduced FM at the dosages of  $\geq 2$  g/d, when administered for  $\geq 12$  weeks. Cinnamon administration resulted in BW and WC reduction in non-linear fashion ( $P = 0.04$ ).

**Conclusions:** Cinnamon supplementation significantly affects obesity measures. It could be recommended as a weight-reducing supplement in obesity management.

© 2019 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

\* Corresponding author. Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, P.O. Box 14155-6117, Tehran, Iran. Fax: +98 21 88984861.

E-mail address: [a-esmailzadeh@tums.ac.ir](mailto:a-esmailzadeh@tums.ac.ir) (A. Esmailzadeh).

## 1. Introduction

Obesity has become a global major health problem [1]. World Health Organization (WHO) defined overweight and obesity as irregular or excessive fat accumulation that poses a threat to health. According to the last WHO report in 2016, 39% of the world's adult ( $\geq 18$  years) population were overweight and 13% had obesity [2]. Obesity is associated with major chronic diseases like cancer, CVD

and, diabetes. It has also a negative effect on individuals' self-esteem due to body shape issues which finally could lead to severe depression and mental health problems [3–7].

Since conventional therapies such as restricted diet and changing lifestyle has not come out so efficacious [8], people are desperate for a new, easier and more successful methods such as supplementation with herbal remedies to reach their ideal body shape. Cinnamon is a flavor additive used to improve odor, taste, and color of meals for a long time. It is derived from the inner bark several tree species from the genus *Cinnamomum* widely spread in the Mediterranean region, Sri Lanka and India [9,10]. The main components exist in cinnamon are cinnamic acid, cinnamaldehyde, eugenol, and coumarin; these components were reported to have antimicrobial properties [11,12]. Cinnamon is also high in antioxidants such as polyphenols and glutathione; therefore, it could be regarded as a powerful anti-inflammatory agent and may protect against cancer [13–17]. It could lower the risk of heart diseases through reducing LDL cholesterol and increasing HDL cholesterol [18–20]. The role of cinnamon in glucose metabolism has been attributed to its effect on insulin sensitivity and stimulating cellular glucose uptake [21–24]. However, studies on anti-obesity properties of cinnamon are controversial and inconsistent. Several clinical trials have suggested that cinnamon consumption has beneficial effects on indicators of body composition [25,26]. In contrast, other did not support such finding [27,28]. To the best of our knowledge, no study has ever summarized findings on this issue. Thus, the current study was designed as a comprehensive systematic review and dose-response meta-analysis of published randomized controlled trials (RCTs) to assess the effects of cinnamon supplementation on body weight (BW), body mass index (BMI), waist circumference (WC), and fat mass percentage (FM) in adults.

## 2. Material and methods

The present study adhered to the Preferred Reporting Items of Systematic Reviews and Meta-Analysis (PRISMA) statement guideline for performing and reporting [29].

### 2.1. Search strategy

We systematically searched electronic databases including PubMed/Medline, Scopus, the Cochrane Library, and Google Scholar to identify clinical trials that examined the effects of cinnamon supplements on obesity indices from inception to September 2018; without any language restriction. The merge of MESH and non-MESH terms were used as follows: (“*Cinnamomum zeylanicum*” [Mesh] OR *Cinnamomum* [Mesh] OR Cinnamon [Title/Abstract] OR Cinnamons [Title/Abstract] OR “*Cinnamomum verum*” [Title/Abstract] OR *Cinnamomum* [Title/Abstract]) AND (“Body Weight” [Mesh] OR “Body Weight Changes” [Mesh] OR “Body Mass Index” [Mesh] OR “Weight Loss” [Mesh] OR “Obesity” [Mesh] OR “Waist Circumference” [Mesh] OR “Obesity, Abdominal” [Mesh] OR “Adipose Tissue” [Mesh] OR “Abdominal Fat” [Mesh] OR “Body Weight” [Title/Abstract] OR “Body Weight Change” [Title/Abstract] OR “Quetelet Index” [Title/Abstract] OR “Body Mass Index” [Title/Abstract] OR BMI [Title/Abstract] OR “Weight Loss” [Title/Abstract] OR “Weight Reduction” [Title/Abstract] OR “Weight Losses” [Title/Abstract] OR Obesity [Title/Abstract] OR “Waist Circumference” [Title/Abstract] OR “Abdominal Obesity” [Title/Abstract] OR “Central Obesity” [Title/Abstract] OR “Visceral Obesity” [Title/Abstract] OR obes\*[Title/Abstract] OR overweight [Title/Abstract] OR “adipose tissue” [Title/Abstract] OR “fat mass” [Title/Abstract] OR adiposity [Title/Abstract] OR “Body Fat” [Title/Abstract] OR “Abdominal Fat” [Title/Abstract]). Also, we manually checked all reference lists of eligible articles, related reviews, and meta-analyses in order to

avoid missing any relevant studies. The PubMed's e-mail alert service was activated to find any new articles in this area that may be published after our search.

### 2.2. Eligibility criteria

The following criteria were considered to select eligible articles; (1) randomized placebo-controlled trials (either parallel or cross-over design) (2) studies that were performed on adult population ( $\geq 18$  years old) (3) Those that provided sufficient data on baseline and final measures of BW or/and BMI or/and WC or/and FM in both cinnamon and control groups (4) Publications that did the intervention with any cinnamon species.

### 2.3. Excluded studies

Articles were excluded if they; (1) were performed on children, pregnant women or animals (2) were not placebo-controlled trials (3) did not provide sufficient information for the outcomes in cinnamon or control groups (4) investigated the effects of Cinnamon along with other ingredients. Unpublished documents and grey literature like conference papers, dissertations, and patents were excluded as well.

### 2.4. Data extraction

Two independent researchers (SMM and HKV) did the study selection whereas a chief investigator (AE) was also present to resolve any controversies. In case of lack of reporting data in the published paper, we contacted the corresponding author to acquire the necessary data. The following data were obtained from each study; first author's name, year of publication, study location, trial duration, type and dosage of cinnamon supplements, mean age and gender of participants, study design, health status of participants, number of subjects in each group, mean and SD of outcome measures at baseline, post-intervention and/or changes in outcome measures from baseline to the end-of-trial. If a study provided multiple data at different time points, only the latest were considered.

### 2.5. Quality assessment

We assessed the quality of included studies by using the Cochrane scoring system [30]. It consists of 7 criteria to assess the risk of bias which are as follows: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other biases. Three scores of yes, no, and unclear could be given to each aforementioned item, which are interpreted as high risk, low risk, and unknown risk respectively (Table 1).

### 2.6. Data synthesis and statistical analysis

Mean change and standard deviation (SD) of the relevant outcomes were used to estimate the overall effect size. Effect sizes for all variables were stated as weighted mean differences (WMDs) and 95% CI. The random-effects model by DerSimonian and Laird method [31] was used to estimate the overall effect sizes. When the within-group changes were not reported, we calculated it through subtracting baseline mean from the final mean value in each group separately. The SDs for mean differences was calculated using this formula:  $SD_{change} = \text{square root} [(SD_{baseline})^2 + (SD_{final})^2 - (2 \times 0.9 \times SD_{baseline} \times SD_{final})]$  [32]. For trials that only reported standard error of the mean (SEM), SD was obtained using the

**Table 1**  
Risk of bias assessment of the studies included in this meta-analysis.

Study. (year)	Random Sequence Generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective outcome reporting	Other sources of bias
Ziegenfuss (2006)	U	U	L	U	L	L	L
Blevins (2007)	U	L	L	L	L	L	L
Akilen (2010)	L	L	L	L	L	L	L
Haghighian (2011)	L	L	L	L	U	L	U
Wainstein (2011)	L	L	L	L	L	H	U
Vafa (2012)	U	U	L	L	L	L	L
Torabi (2016)	L	L	H	H	L	L	U
Gupta (2017)	U	L	L	L	L	L	L
Borzoei (2017)	L	L	L	L	L	L	L
Hajimonfarednejad (2018)	L	U	L	L	L	L	L
Nakhaei (2018)	L	L	H	H	L	L	L
Zare (2018)	U	L	L	L	L	L	L

U; unclear risk of bias, L; low risk of bias, H; high risk of bias.

following formula:  $SD = SEM \times \sqrt{n}$ , where “n” is the number of subjects in each group.

Heterogeneity between studies was assessed by Cochrane's Q test (significance point at  $P < 0.1$ ) and  $I^2$  index. To identify potential sources of heterogeneity, a pre-defined subgroup analysis based on cinnamon dosage, duration of supplementation, mean age, sex, baseline BMI, and health status of subjects was performed. To determine the impact of each trial on the pooled effect size, a sensitivity analysis was performed. Studies were removed one by one and the analysis was repeated [33]. The non-linear potential effects of cinnamon dosage (g/day) and intervention duration (weeks) were assessed by fractional polynomial modeling [34]. Publication bias assessment was done using visual inspection of funnel plots and statistically with Egger's regression test. All statistical analyses were performed using STATA software version 14 (STATA Corp, College Station, Texas).  $P < 0.05$  was considered statistically significant.

### 3. Results

#### 3.1. Study selection

In our primary search, we detected a total of 679 records; 120 duplicates were identified and removed. After screening based on title and abstract, 42 articles were retained for further evaluation. In the next step, 30 papers were excluded based on the full-text review. These exclusions were due to the following reasons: Irrelevant ( $n = 4$ ), studied adolescents ( $n = 1$ ), administered cinnamon in combination with other components ( $n = 4$ ), duplicate dataset ( $n = 3$ ), those without a placebo group ( $n = 4$ ), studies that did not provide sufficient data for outcomes ( $n = 14$ ). Finally, 12 trials were included in this meta-analysis [25–28,35–42]. Of these, 10 trials reported the effect of cinnamon on BW [26–28,36–42], 11 articles on BMI [26–28,35–42], 4 articles on WC [27,28,36,38], and 5 trials on FM [25,26,37,38,41,42]. The process of study identification is presented in Fig. 1.

#### 3.2. Characteristics of the included studies

The general characteristics of the included studies are outlined in Table 2. These studies were published between 2006 and 2018 and were carried out in the USA [25,35], United Kingdom [28], Israel [36], India [38], and Iran [26,27,37,39–42]. The follow-up period ranged from 8 to 16 weeks. Daily recommended dosage of cinnamon varied between 1 and 10 g in these studies. The design of all the included trials was parallel. All studies were done on both

genders except for four trials that were done exclusively on women [27,39,41,42]. The sample size in the included trials ranged from 18 [41] to 138 [26]. In total, 786 subjects were enrolled in these studies, of which 395 individuals allocated to cinnamon supplementation group and 391 subjects to the control group. The mean age of the participants ranged from 21.8 to 63.9 years old and mean baseline BMI varied from 27.6 to 33.6 kg/m<sup>2</sup>. Participants in these studies were patients with type 2 diabetes [26,28,35–37,40,41], pre-diabetic subjects [25], individuals with the metabolic syndrome [38], overweight women [42], and those with polycystic ovary syndrome [27,39].

Based on the present systematic review, 4 trials reported reduced body weight with cinnamon [26,37–39], while 6 studies failed to find any significant effect on BW [27,28,36,40–42]. In terms of changes in BMI, a significant reduction was observed in 4 trials [26,37–39], while 7 studies did not find such an effect [27,28,35,36,40–42]. Few studies assessed the effect of cinnamon on WC [27,28,36,38]. Based on their findings, one trial reported the favorable effect of cinnamon intake on WC reduction [38] and others found no significant effect [27,28,36]. All studies that examined the effect of cinnamon supplementation on FM found a significant reduction in FM [26,37–39] except for one publication [41].

#### 3.3. Effect of cinnamon supplementation on BW

Totally, 10 eligible studies with 12 treatment arms, including a total of 707 participants, examined the effect of cinnamon intake on body weight. Combining their findings based on random-effects model, we found that body weight was significantly reduced after cinnamon supplementation (Weighted Mean Differences (WMD):  $-1.02$  kg, 95% CI:  $-1.66$  to  $-0.38$ ,  $P = 0.002$ ) compared to the control group, with a significant between-study heterogeneity ( $I^2 = 80.1\%$ ,  $P < 0.001$ ) (Fig. 2A). Duration of intervention and participants' gender did not explain this heterogeneity. However, the mean age of study participants, and their health status and baseline BMI could explain the heterogeneity. Among subjects aged  $< 50$  years old, cinnamon administration resulted in a greater reduction in BW (WMD:  $-1.17$  kg, 95% CI:  $-2.17$ ,  $-0.17$ ;  $P < 0.001$ ) than older subjects (WMD:  $-0.85$  kg, 95% CI:  $-1.81$ ,  $0.11$ ;  $P = 0.09$ ). Reduction in BW after cinnamon consumption was significant in subjects with baseline BMI  $\geq 30$  kg/m<sup>2</sup> (WMD:  $-1.93$  kg, 95% CI:  $-3.76$ ,  $-0.10$ ;  $P = 0.03$ ); however, it did not influence BW in overweight subjects (WMD:  $-0.68$  kg, 95% CI:  $-1.39$ ,  $0.02$ ;  $P = 0.06$ ). Based on health status, the effect of cinnamon was significantly greater in women with PCOS (WMD:  $-0.51$  kg, 95% CI:  $-0.83$ ,  $-0.19$ ;  $P = 0.002$ ) than




Fig. 1. Flow chart for study identification and selection into the meta-analysis.

type 2 diabetic patients (WMD:  $-0.85$  kg, 95% CI:  $-1.81, 0.11$ ;  $P = 0.09$ ) and apparently healthy subjects (WMD:  $-1.52$  kg, 95% CI:  $-3.23, 0.18$ ;  $P = 0.08$ ). All these findings were provided in Table 3.

#### 3.4. Effect of cinnamon supplementation on BMI

Overall, 11 trials with 13 treatment arms, including a total of 764 subjects, reported the effect of cinnamon consumption on BMI. Pooled results from the random-effects model showed a significant effect of cinnamon intake on BMI; such that this intervention resulted in a significant reduction in BMI compared with placebo (WMD:  $-0.51$  kg/m<sup>2</sup>, 95% CI:  $-0.74, -0.28$ ,  $P < 0.001$ ). A significant between-study heterogeneity was reached ( $I^2 = 89.9\%$ ,  $P < 0.001$ ) (Fig. 2B). In the subgroup analysis, we found that gender and health status of study participants explained this heterogeneity. Studies that were conducted on both sexes revealed a greater reduction in BMI (WMD:  $-0.55$  kg/m<sup>2</sup>, 95% CI:  $-0.86, -0.25$ ;  $I^2: 92.6\%$ ,  $P < 0.001$ ) than those performed on women (WMD:  $-0.43$  kg/m<sup>2</sup>, 95% CI:  $-0.92, 0.05$ ;  $I^2: 86.4\%$ ,  $P = 0.08$ ). In addition, based on participants' health status, a significant reduction in BMI was found in trials that were performed on individuals with type 2 diabetes (WMD:  $-0.41$  kg/m<sup>2</sup>, 95% CI:  $-0.68, -0.14$ ;  $I^2: 89.5\%$ ,  $P = 0.004$ ) and apparently healthy individuals (WMD:  $-0.91$  kg/m<sup>2</sup>, 95% CI:  $-1.48, -0.33$ ;  $I^2: 75.9\%$ ,  $P < 0.001$ ) compared with those

conducted on PCOS patients (WMD:  $-0.36$  kg/m<sup>2</sup>, 95% CI:  $-0.92, 0.19$ ;  $I^2: 77.7\%$ ,  $P = 0.20$ ).

#### 3.5. Effect of cinnamon supplementation on WC

Pooling effect sizes from 4 publications including 292 participants, we found that cinnamon administration had a significant effect on WC compared with placebo (WMD:  $-2.40$  cm, 95% CI:  $-4.48, -0.33$ ,  $P = 0.02$ ), with a considerable between-study heterogeneity ( $I^2 = 90.7\%$ ,  $P < 0.001$ ) (Fig. 2C). Subgroup analysis based on cinnamon dosage ( $<2$  vs.  $\geq 2$  g/d), baseline BMI status ( $<30$  vs.  $\geq 30$  kg/m<sup>2</sup>), and mean age of the subjects ( $<50$  vs.  $\geq 50$  years) revealed that these factors did not explain the heterogeneity.


#### 3.6. Effect of cinnamon supplementation on FM

The impact of cinnamon supplementation on FM was assessed in 5 trials with 6 treatment arms including 349 participants. The pooled estimates revealed that in subjects who consumed cinnamon supplements, FM significantly decreased compared to those who took placebo (WMD:  $-1.02\%$ , 95% CI:  $-1.80, -0.24$ ,  $P = 0.01$ ). There was a significant between-study heterogeneity ( $I^2 = 86.3\%$ ,  $P < 0.001$ ) (Fig. 2D). Subgroup analysis revealed that cinnamon dosage, duration of intervention, health status of participants, subjects' age and gender explained this heterogeneity. In these analyses, we found that the effect of cinnamon administration on

**Table 2**  
General demographic characteristics of the included studies.

Code/First Author (year)	Location	Study Design	Population	Gender	Sample size Cinnamon/ Placebo	Duration (week)	Mean age (year)	Baseline BMI (kg/m <sup>2</sup> )	Intervention		Outcome; (yes/no)
									Treatment group	Control group	
1. Ziegenfuss (2006)	USA	Randomized, double-blind, placebo-controlled parallel trial	Pre-diabetic subjects	Both	12/10	12	46.3	32.3	250 mg capsules Cinnulin PF, equivalent to 5 g ground cinnamon. 2 capsules per day (10 g of whole cinnamon powder)	Placebo	- FM/yes
2. Blevins (2007)	USA	Randomized, double-blind, placebo-controlled parallel trial	Type 2 diabetes	Both	29/28	13	63.9	32.5	1 g cinnamon capsules	Placebo (wheat flour)	- BMI/no
3. Akilen (2010)	United kingdom	Randomized, double-blind, placebo-controlled parallel trial	Type 2 diabetic patients	Both	30/28	12	54.9	33.3	2 g cinnamon capsules	Placebo	- BW/no - BMI/no - WC/no
4. Haghghian (2011)	Iran	Randomized, double-blind, placebo-controlled parallel trial	Type 2 diabetic patients	Both	30/30	8	59.1	28	1.5 g/d of whole cinnamon powder capsules	Placebo	- BW/no - BMI/no
5. Wainstein (2011)	Israel	Randomized, double-blind, placebo-controlled parallel trial	Type 2 Diabetes	Both	29/30	12	61.7	29.8	3 capsules each contain 400 mg of freshly ground cinnamon (1200 mg total)	Placebo capsules contained 400 mg of microcrystalline cellulose	- BW/no - BMI/no - WC/no
6. Vafa (2012)	Iran	Randomized, double-blind, placebo-controlled parallel trial	Type 2 Diabetic Patients	Both	19/18	8	54.1	29.2	500 mg cinnamon capsules. 2 capsules 3 times a day (3000 mg total)	Placebo	- BW/yes - BMI/yes - FM/yes
7. Torabi (2016)	Iran	Randomized, placebo-controlled parallel trial	Type 2 diabetes	Women	9/9	8	53.6	29	500 mg cinnamon capsules 3 times a day (1500 mg)	Placebo	- BW/no - BMI/no - FM/no
8. Torabi (2016)	Iran	Randomized, placebo-controlled parallel trial	Type 2 diabetes	Women	9/9	8	51.2	29	500 mg cinnamon capsules 3 times a day (1500 mg) + exercise	Placebo + exercise	- BW/no - BMI/no - FM/no
9. Gupta (2017)	India	Randomized, double-blind, placebo-controlled parallel trial	Metabolic syndrome	Both	58/58	16	44.3	33.6	6 cinnamon capsules (3000 mg total)	Placebo (wheat flour)	- BW/yes - BMI/yes - WC/yes - FM/yes
10. Borzoei (2017)	Iran	Randomized, double-blind, placebo-controlled parallel trial	Polycystic ovary syndrome	Women	42/42	8	29.3	30.7	3 cinnamon capsules, each one contain 500 mg cinnamon (1500 mg total)	Placebo capsules (wheat flour)	- BW/yes - BMI/yes
11. Hajimonfarednejad (2018)	Iran	Randomized, double-blind, placebo-controlled parallel trial	Polycystic ovary syndrome	Women	29/30	12	28.6	27.6	500 mg cinnamon capsules 3 times (1500 mg total)	Placebo	- BW/no - BMI/no - WC/no
12. Nakhaei (2018)	Iran	Randomized, placebo-controlled parallel trial	Overweight subjects	Women	15/15	8	22.4	28.9	1 g cinnamon capsules	Placebo	- BW/no - BMI/no
13. Nakhaei (2018)	Iran	Randomized, placebo-controlled parallel trial	Overweight subjects	Women	15/15	8	21.8	28.2	1 g cinnamon capsules + exercise	Placebo + exercise	- BW/no - BMI/no
14. Zare (2018)	Iran	Randomized, triple -blind, placebo-controlled parallel trial	Type 2 diabetes	Both	69/69	13	52.1	29.9	1 g cinnamon capsules	Placebo	- BW/yes - BMI/yes - FM/yes

Abbreviations: BW; body weight, BMI; body mass index, WC; waist circumference, FM; fat mass.



**Fig. 2.** Forest plot detailing weighted mean difference and 95% confidence intervals (CIs) for the effect of cinnamon supplementation on A) body weight, B) BMI, C) waist circumference, and D) fat mass.

FM was significant at the dosages of  $\geq 2$  g/d (WMD:  $-1.08\%$ , 95% CI:  $-1.71, -0.49$ ;  $P = 0.001$ ), in trials lasting  $\geq 12$  weeks (WMD:  $-1.60\%$ , 95% CI:  $-2.05, -1.15$ ;  $P < 0.001$ ), in studies performed on subjects with obesity (WMD:  $-1.46\%$ , 95% CI:  $-2.06, -0.87$ ;  $P < 0.001$ ), in studies on people with a mean age of  $< 50$  years old (WMD:  $-1.19\%$ , 95% CI:  $-2.28, -0.10$ ;  $P < 0.001$ ), and in trials conducted of both gender (WMD:  $-1.28\%$ , 95% CI:  $-2.87, -0.69$ ;  $P < 0.001$ ).

### 3.7. Dose-responses association between cinnamon supplementation and outcomes

Based on the dose-response evaluation, cinnamon administration resulted in reduced BW ( $P_{\text{non-linearity}} = 0.04$ ) and WC in a non-linear fashion ( $P_{\text{non-linearity}} = 0.04$ ). Greater effects were seen at doses of 1.5 g/d. We did not find a significant non-linear relationship with BMI ( $P_{\text{non-linearity}} = 0.18$ ), and FM ( $P_{\text{non-linearity}} = 0.47$ ) (Fig. 3A-D). Moreover, the duration of cinnamon supplementation did not show a significant non-linear association with BW ( $P_{\text{non-linearity}} = 0.07$ ), BMI ( $P_{\text{non-linearity}} = 0.39$ ), WC ( $P_{\text{non-linearity}} = 0.06$ ), and FM ( $P_{\text{non-linearity}} = 0.50$ ) (Fig. 4A-D).

### 3.8. Sensitivity analysis

To explore the impact of each single study on the overall effect size, we omitted each trial from the analysis, step by step. We found

no significant effect of any individual study on the overall effect sizes of BW, BMI, WC, and FM.

### 3.9. Publication bias

Visual inspection of the funnel plots indicated no evidence of asymmetry in the effects of cinnamon supplementation on anthropometric measures and body composition (Fig. 5). These observations were approved by the use of Egger's regression tests for BW ( $P = 0.77$ ), BMI ( $P = 0.32$ ), WC ( $P = 0.12$ ), and FM ( $P = 0.83$ ).

## 4. Discussion

In the present systematic review and meta-analysis, we summarized available records from 12 RCTs which examined the effects of cinnamon supplementation on anthropometric measures including BW, BMI, WC, and FM in adults. Our findings revealed that cinnamon supplementation can significantly reduce BW, BMI, WC, and FM. In the subgroup analyses, we found a greater reduction in BW in subjects aged  $< 50$  years old, those with a baseline BMI of  $\geq 30$  kg/m<sup>2</sup>. The cinnamon administrations significantly reduced FM at the dosages of  $\geq 2$  g/d, when administered for  $\geq 12$  weeks.


Our findings were in agreement with a recent systematic review which proposed the potential anti-obesity effects of cinnamon supplementation [43]. In a recent meta-analysis of RCTs, flavanols, a major component of cinnamon, showed a potential role against obesity [44]. Such results were also observed for polyphenols [45].

**Table 3**  
Subgroup analysis of included randomized controlled trials in meta-analysis of the effect of cinnamon supplementation on obesity indices.

Group	No. of trials	WMD (95% CI)	P value	I <sup>2</sup> (%)	P-heterogeneity	P for between subgroup heterogeneity
<b>Body weight</b>						
Cinnamon dosage						
<2 g	9	-0.69 (-1.36, -0.02)	0.04	72.2	<0.001	0.009
≥2 g	3	-1.94 (-3.66, -0.23)	0.02	89.8	<0.001	
Duration (week)						
<12 week	7	-0.47 (-0.75, -0.18)	0.001	0.0	0.74	<0.001
≥12 week	5	-1.73 (-2.69, -0.77)	<0.001	79	0.001	
Baseline BMI						
Obese (≥30)	3	-1.93 (-3.76, -0.10)	0.03	93.5	<0.001	0.37
Overweight (25 < BMI<30)	9	-0.68 (-1.39, 0.02)	0.06	66.4	0.002	
Mean age						
<50 years	5	-1.17 (-2.17, -0.17)	0.02	82.6	<0.001	0.02
≥50 years	7	-0.85 (-1.81, 0.11)	0.09	78.0	<0.001	
Gender						
Females	6	-0.53 (-0.82, -0.23)	<0.001	0.0	0.83	<0.001
Both	6	-1.33 (-2.42, -0.24)	0.02	85.4	<0.001	
Health status						
Type 2 diabetes	7	-0.85 (-1.81, 0.11)	0.09	78.0	<0.001	<0.001
PCOS	2	-0.51 (-0.83, -0.19)	0.002	0.0	0.38	
Apparently healthy	3	-1.52 (-3.23, 0.18)	0.08	82.6	0.003	
<b>Body mass index</b>						
Cinnamon dosage						
<2 g	10	-0.45 (-0.71, -0.18)	0.02	90.5	<0.001	0.01
≥2 g	3	-0.70 (-1.30, -0.12)	0.01	89.0	<0.001	
Duration (week)						
<12 week	7	-0.43 (-0.81, -0.04)	0.03	84.6	0.04	0.09
≥12 week	6	-0.59 (-0.93, -0.25)	0.001	93.5	<0.001	
Baseline BMI						
Obese (≥30)	4	-0.51 (-0.84, -0.19)	0.002	91.3	<0.001	<0.001
Overweight (25 < BMI<30)	9	-0.49 (-0.80, -0.19)	0.001	81.3	<0.001	
Mean age						
<50 years	5	-0.65 (-1.25, -0.06)	0.03	92.3	<0.001	0.48
≥50 years	8	-0.41 (-0.68, -0.14)	0.003	89.5	<0.001	
Gender						
Females	6	-0.43 (-0.92, 0.05)	0.08	86.4	0.03	0.25
Both	7	-0.55 (-0.86, -0.25)	<0.001	92.6	<0.001	
Health status						
Type 2 diabetes	8	-0.41 (-0.68, -0.14)	0.004	89.5	<0.001	<0.001
PCOS	2	-0.36 (-0.92, 0.19)	0.2	77.7	0.03	
Apparently healthy	3	-0.91 (-1.48, -0.33)	<0.001	75.9	0.02	
<b>Waist circumference</b>						
Cinnamon dosage						
<2 g	2	-1.56 (-2.62, -0.49)	0.004	0.0	0.46	<0.001
≥2 g	2	-3.37 (-6.30, -0.45)	0.02	92.5	<0.001	
Baseline BMI						
Obese (≥30)	2	-3.37 (-6.30, -0.45)	0.02	92.5	<0.001	<0.001
Overweight (25 < BMI<30)	2	-1.56 (-2.62, -0.49)	0.004	0.0	0.46	
Mean age						
<50 years	2	-3.31 (-6.30, -0.32)	0.03	94.8	<0.001	<0.001
≥50 years	2	-1.53 (-2.78, -0.27)	0.01	0.0	0.45	
<b>Fat mass</b>						
Cinnamon dosage						
<2 g	3	-0.92 (-2.50, 0.65)	0.25	93.8	<0.001	0.82
≥2 g	3	-1.08 (-1.71, -0.49)	0.001	50.5	0.13	
Duration (week)						
<12 week	3	-0.55 (-1.80, 0.69)	0.38	91.5	<0.001	<0.001
≥12 week	3	-1.60 (-2.05, -1.15)	<0.001	0.0	0.78	
Baseline BMI						
Obese (≥30)	2	-1.46 (-2.06, -0.87)	<0.001	0.0	0.81	0.07
Overweight (25 < BMI<30)	4	-0.85 (-1.91, 0.19)	0.11	91.0	<0.001	
Mean age						
<50 years	2	-1.19 (-2.28, -0.10)	<0.001	0.0	0.81	0.07
≥50 years	4	-0.85 (-1.91, 0.19)	0.11	91.0	<0.001	
Gender						
Females	2	-0.50 (-2.85, 1.85)	0.67	95.7	<0.001	0.02
Both	4	-1.28 (-1.87, -0.69)	<0.001	61.3	0.05	

In addition to its effect on body weight, cinnamon supplementation has also been shown to improve weight-related disorders including blood triglycerides, total cholesterol, HDL-C levels, fasting plasma glucose, and HbA1c levels in humans [19,46,47]. The beneficial effects of cinnamon supplementation on inhibiting pancreatic  $\alpha$ -

amylase and reducing intestinal glucose absorption, stimulating cellular glucose uptake and glycogen synthesis, inhibiting gluconeogenesis, stimulating insulin receptor activity, improving weight loss, increasing insulin levels, and reducing fasting blood glucose were also seen in *in vitro* and *in vivo* studies [21]. Overall, these



**Fig. 3.** Non-linear dose-response relations between cinnamon dosage (g/d) and unstandardized mean difference in (A) BW, (B) BMI, (C) WC, and (D) FM. The 95% CI is demonstrated in the shaded regions.

findings indicate that cinnamon supplementation could be regarded as a potential healthy spice for human body.

Cinnamon can delay gastric emptying, increase glucosidase enzymes and inhibit ATPase of intestinal brush borders; so it can reduce glucose absorption in the small intestine [48–50]. Furthermore, cinnamon increases glucose transporter 4 (GLUT4), activates glycogen synthase and inhibits glycogen synthase kinase-3  $\beta$  [12,49]. All these actions are decreasing glucose levels and in turn its conversion to glycogen. Methyl Hydroxy chalcone polymers (MHCP) in cinnamon make adipose cells more reactive to insulin by activating the insulin-receptor kinase and inhibiting the insulin-receptor-phosphatase, which increases insulin sensitivity and helps increasing body metabolism [51,52]. Flavonoids and phenolic complexes like epicatechin, catechin, and procyanidin B2 in cinnamon can decrease the absorption of glucose in the intestine, decrease glycogenolysis, and increase glycogen synthesis. Furthermore, these actions can decrease chylomicron absorption [48]. Reducing glucose and chylomicron absorption leads to reduction in the synthesis and storage of fat and improvement in anthropometric measures [53].


Our meta-analysis indicated that cinnamon supplementation is more effective when it was administered to young adults, subjects with obesity, at higher dosages and longer duration. Serban et al. in a meta-analysis in 2017 showed that increasing duration of cinnamon administration has a significant effect on reduced blood triglycerides and cholesterol [48]. In general, the antioxidant effects of these supplements is improved when it is prescribed in higher dosage for longer duration [54]. Furthermore, Kim et al. in an animal study indicated that high doses of cinnamon extract (200 mg/kg) was most effective in decreasing the blood glucose levels

compared with low doses [55]. With regards to age, it must be taken into account that age-related obesity plays an important role in the dysregulation of inflammatory cytokine production. It is possible that elevated inflammation in older people might hinder observing the effects of cinnamon [56]. The anti-inflammatory protein, tristetraprolin (TTP) is reduced in people with obesity, but it is increased by cinnamon. TTP plays an important role in insulin signaling, glucose transport, and gluconeogenesis [57]. So increasing TTP in people with obesity can explain greater weight change in these participants by cinnamon intake.


#### 4.1. Strengths and limitations

To the best of our knowledge, this is the first meta-analysis on the effects of cinnamon supplementation on obesity measures. This study included an adequate number of trials on the effects of cinnamon intake on BW and BMI, while the number of trials about waist circumference and fat mass might be insufficient. Therefore, our findings of the latest two measures should be interpreted with caution. Although in some cases, some sort of between-study heterogeneity was found, we found potential sources of this heterogeneity in our analyses. Despite this, some limitations should be noted. First, included studies have used different spices of cinnamon, which might influence our findings. Future studies are recommended to focus on the most effective spice of cinnamon. Second, these studies were carried out on participants with different health conditions and various age groups. Although we considered these factors in our subgroup analyses, this must be considered in the interpretation.





**Fig. 4.** Non-linear dose-response relations between duration of intervention (weeks) and unstandardized mean difference in (A) BW, (B) BMI, (C) WC, and (D) FM. The 95% CI is demonstrated in the shaded regions.



**Fig. 5.** Funnel plot representing publication bias in the studies reporting the effect of cinnamon supplementation on (A) BW, (B) BMI, (C) WC, and (D) FM.

## 5. Conclusion

The current meta-analysis pooled results from 12 RCTs including 786 participants. Our findings indicated that cinnamon supplementation can significantly reduce BW, BMI, WC, and FM. Greater effects on BW were observed in subjects aged <50 years old, those with a baseline BMI of  $\geq 30$  kg/m<sup>2</sup>. The cinnamon administrations significantly reduced FM at the dosages of  $\geq 2$  g/d, when administered for  $\geq 12$  weeks.

## Author contributions

SMM and AE conceived the study. The literature search and screening data were done by SMM and HKV. Data extraction and quality assessment were performed independently by JR, ASH, and BL. SMM, JR and AE analyzed and interpreted data and wrote the manuscript. AE supervised the study. All authors read and approved the final manuscript.

## Funding

None.

## Conflicts of interest

The authors declared no conflicts of interest.

## Acknowledgements

None.

## References

- [1] Vandevijvere S, Chow CC, Hall KD, Umali E, Swinburn BA. Increased food energy supply as a major driver of the obesity epidemic: a global analysis. *Bull World Health Organ* 2015;93(7):446–56.
- [2] Organization WH. Obesity and overweight factsheet from the WHO. *Health (N Y)*. 2017.
- [3] Cai H, Shu XO, Gao YT, Li H, Yang G, Zheng W. A prospective study of dietary patterns and mortality in Chinese women. *Epidemiology* 2007;18(3):393–401.
- [4] Faith MS, Butryn M, Wadden TA, Fabricatore A, Nguyen AM, Heymsfield SB. Evidence for prospective associations among depression and obesity in population-based studies. *Obes Rev* 2011;12(5):e438–53.
- [5] Dehal A, Garrett T, Tedders SH, Arroyo C, Afriyie-Gyawu E, Zhang J. Body mass index and death rate of colorectal cancer among a national cohort of U.S. adults. *Nutr Canc* 2011;63(8):1218–25.
- [6] Willey JZ, Rodriguez CJ, Carlino RF, Moon YP, Paik MC, Boden-Albala B, et al. Race-ethnic differences in the association between lipid profile components and risk of myocardial infarction: the Northern Manhattan Study. *Am Heart J* 2011;161(5):886–92.
- [7] Steele CB, Thomas CC, Henley SJ, Massetti GM, Galuska DA, Agurs-Collins T, et al. Vital signs: trends in incidence of cancers associated with overweight and obesity - United States, 2005–2014. *MMWR Morb Mortal Wkly Rep* 2017;66(39):1052–8.
- [8] MacLean PS, Wing RR, Davidson T, Epstein L, Goodpaster B, Hall KD, et al. NIH working group report: innovative research to improve maintenance of weight loss. *Obesity* 2015;23(1):7–15.
- [9] Ranasinghe P, Pigeira S, Premakumara GAS, Galappaththy P, Constantine GR, Katulanda P. Medicinal properties of 'true' cinnamon (*Cinnamomum zeylanicum*): a systematic review. *BMC Complement Altern Med* 2013;13:275.
- [10] Kumar K, Issac A, Ninan E, Kuttan R, Maliakel B. Enhanced anti-diabetic activity of polyphenol-rich de-coumarinated extracts of *Cinnamomum cassia*. *J Funct Foods* 2014;10:54–64.
- [11] Shan B, Cai YZ, Brooks JD, Corke H. Antibacterial properties and major bioactive components of cinnamon stick (*Cinnamomum burmannii*): activity against foodborne pathogenic bacteria. *J Agric Food Chem* 2007;55(14):5484–90.
- [12] Broadhurst CL, Polansky MM, Anderson RA. Insulin-like biological activity of culinary and medicinal plant aqueous extracts *in vitro*. *J Agric Food Chem* 2000;48(3):849–52.
- [13] Sedighi M, Nazari A, Faghihi M, Rafeian-Kopaei M, Karimi A, Moghimian M, et al. Protective effects of cinnamon bark extract against ischemia-reperfusion injury and arrhythmias in rat. *Phytother Res* 2018;1–9.
- [14] Ka H, Park HJ, Jung HJ, Choi JW, Cho KS, Ha J, et al. Cinnamaldehyde induces apoptosis by ROS-mediated mitochondrial permeability transition in human promyelocytic leukemia HL-60 cells. *Cancer Lett* 2003;196(2):143–52.
- [15] Lee C, Hong D, Han S, Park S, Kim H, Kwon BM, et al. Inhibition of human tumor growth by 2'-hydroxy- and 2'-benzoyloxy-cinnamaldehydes. *Planta Med* 1999;65(03):263–6.
- [16] Kim JC, Deng JS, Chiu CS, Hou WC, Huang SS, Shie PH, et al. Anti-inflammatory activities of *Cinnamomum cassia* constituents *in vitro* and *in vivo*. *Evid Based Complement Altern Med* 2012;2012:429320.
- [17] Gunawardena D, Karunaweera N, Lee S, van Der Kooy F, Harman DG, Raju R, et al. Anti-inflammatory activity of cinnamon (*C. zeylanicum* and *C. cassia*) extracts - identification of E-cinnamaldehyde and o-methoxy cinnamaldehyde as the most potent bioactive compounds. *Food Funct* 2015;6(3):910–9.
- [18] Askari F, Rashidkhani B, Hekmatdoost A. Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients. *Nutr Res* 2014;34(2):143–8.
- [19] Allen RW, Schwartzman E, Baker WL, Coleman CI, Phung OJ. Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis. *Ann Fam Med* 2013;11(5):452–9.
- [20] Khan A, Safdar M, Ali Khan MM, Khattak KN, Anderson RA. Cinnamon improves glucose and lipids of people with type 2 diabetes. *Diabetes Care* 2003;26(12):3215–8.
- [21] Ranasinghe P, Jayawardana R, Galappaththy P, Constantine GR, de Vas Gunawardana N, Katulanda P. Efficacy and safety of 'true' cinnamon (*Cinnamomum zeylanicum*) as a pharmaceutical agent in diabetes: a systematic review and meta-analysis. *Diabet Med* 2012;29(12):1480–92.
- [22] Lu T, Sheng H, Wu J, Cheng Y, Zhu J, Chen Y. Cinnamon extract improves fasting blood glucose and glycosylated hemoglobin level in Chinese patients with type 2 diabetes. *Nutr Res* 2012;32(6):408–12.
- [23] Cao H, Polansky MM, Anderson RA. Cinnamon extract and polyphenols affect the expression of tristetraprolin, insulin receptor, and glucose transporter 4 in mouse 3T3-L1 adipocytes. *Arch Biochem Biophys* 2007;459(2):214–22.
- [24] Crawford P. Effectiveness of cinnamon for lowering hemoglobin A1C in patients with type 2 diabetes: a randomized, controlled trial. *J Am Board Fam Med* 2009;22(5):507–12.
- [25] Ziegenfuss TN, Hofheins JE, Mendel RW, Landis J, Anderson RA. Effects of a water-soluble cinnamon extract on body composition and features of the metabolic syndrome in pre-diabetic men and women. *J Int Soc Sports Nutr* 2006;3:45.
- [26] Zare R, Nadjarzadeh A, Zarshenas MM, Shams M, Heydari M. Efficacy of cinnamon in patients with type II diabetes mellitus: a randomized controlled clinical trial. *Clin Nutr* 2019 Apr;38(2):549–56.
- [27] Hajimonfarednejad M, Nimrouzi M, Heydari M, Zarshenas MM, Raei MJ, Jahromi BN. Insulin resistance improvement by cinnamon powder in polycystic ovary syndrome: a randomized double-blind placebo controlled clinical trial. *Phytother Res* 2018;32(2):276–83.
- [28] Akilen R, Tsiami A, Devendra D, Robinson N. Glycated haemoglobin and blood pressure-lowering effect of cinnamon in multi-ethnic Type 2 diabetic patients in the UK: a randomized, placebo-controlled, double-blind clinical trial. *Diabet Med* 2010;27(10):1159–67.
- [29] Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med* 2009;151(4):264–9.
- [30] Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343(2):d5928.
- [31] DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. *Contemp Clin Trials* 2007;28(2):105–14.
- [32] Borenstein M, Hedges LV, Higgins JP, Rothstein HR. *Introduction to meta-analysis*. John Wiley & Sons; 2011.
- [33] Sahebkar A. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. *Phytother Res* 2014;28(5):633–42.
- [34] Fan J. *Local polynomial modelling and its applications: monographs on statistics and applied probability* 66. Routledge; 2018.
- [35] Blevins SM, Leyva MJ, Brown J, Wright J, Scofield RH, Aston CE. Effect of cinnamon on glucose and lipid levels in Non-insulin-dependent type 2 diabetes. *Diabetes Care* 2007;30(9):2236–7.
- [36] Wainstein J, Stern N, Heller S, Boaz M. Dietary cinnamon supplementation and changes in systolic blood pressure in subjects with type 2 diabetes. *J Med Food* 2011;14(12):1505–10.
- [37] Vafa M, Mohammadi F, Shidfar F, Sormaghi MS, Heidari I, Golestan B, et al. Effects of cinnamon consumption on glycemic status, lipid profile and body composition in type 2 diabetic patients. *Int J Prev Med* 2012;3:531.
- [38] Jain SG, Puri S, Misra A, Gulati S, Mani K. Effect of oral cinnamon intervention on metabolic profile and body composition of Asian Indians with metabolic syndrome: a randomized double-blind control trial. *Lipids Health Dis* 2017;16:113.
- [39] Borzoei A, Rafraf M, Asghari-Jafarabadi M. Cinnamon improves metabolic factors without detectable effects on adiponectin in women with polycystic ovary syndrome. *Asia Pac J Clin Nutr* 2018;27:556.
- [40] Haghghian HK, Naimi AF, Gargari BP, Ali-Asgharzadeh A, Nemat A. Effect of cinnamon supplementation on blood glucose and lipid levels in type2 diabetic patients. *JPS* 2011;2:2008–4978.

- [41] Torabi S, Asad M, Tabrizi A. The effect of endurance training with cinnamon supplementation on plasma concentrations of liver enzymes (ALT,AST) in women with type II diabetes. *Tehran Univ Med Juniversity medical journal* 2016;433–41.
- [42] Nakhaei K, Ghofrani M, Bakhsheshi M, Nakhaei H. Effect of circuit resistance training and cinnamon supplement on body composition and omentin-1 in overweight women. *Iran J Obstet Gynecol Infertil* 2018;74–82.
- [43] Mollazadeh H, Hosseinzadeh H. Cinnamon effects on metabolic syndrome: a review based on its mechanisms. *Iran J Basic Med Sci* 2016;19:1258.
- [44] Akhlaghi M, Ghobadi S, Mohammad Hosseini M, Gholami Z, Mohammadian F. Flavanols are potential anti-obesity agents, a systematic review and meta-analysis of controlled clinical trials. *Nutr Metabol Cardiovasc Dis* 2018;28(7):675–90.
- [45] Farhat G, Drummond S, Al-Dujaili EAS. Polyphenols and their role in obesity management: a systematic review of randomized clinical trials. *Phytother Res* 2017;31(7):1005–18.
- [46] Maieran SM, Serban MC, Sahebkar A, Ursoniu S, Serban A, Penson P, et al. The effects of cinnamon supplementation on blood lipid concentrations: a systematic review and meta-analysis. *J Clin Lipidol* 2017;11(6):1393–406.
- [47] Banach R, Tsiami A, Devendra D, Robinson N. Cinnamon in glycaemic control: systematic review and meta analysis. *Clin Nutr* 2012;31(5):609–15.
- [48] Solomon TPJ, Blannin AK. Effects of short-term cinnamon ingestion on *in vivo* glucose tolerance. *Diabetes Obes Metab* 2007;9(6):895–901.
- [49] Kirkham S, Akilen R, Sharma S, Tsiami A. The potential of cinnamon to reduce blood glucose levels in patients with type 2 diabetes and insulin resistance. *Diabetes Obes Metab* 2009;11(12):1100–13.
- [50] Hlebowicz J, Darwiche G, Björgell O, Almér L-O. Effect of cinnamon on postprandial blood glucose, gastric emptying, and satiety in healthy subjects-. *Am J Clin Nutr* 2007;85(6):1552–6.
- [51] Supriani A, Chasanah N, Effendy HVV, Sari SM, Mardiana HR, Widiyaswari TA. Effectiveness of green tea feeding to decrease cholesterolin hipercolesterol patients at village tunggal pager district punggging mojokerto regency. *Int J Nurs Midwifery Sci* 2018;2:20–6.
- [52] Al Jamal AR. Effects of cinnamon on blood glucose and lipids levels in diabetic patients (Type1). *Afr J Biochem Res* 2009;3:181–4.
- [53] Utzschneider KM, Kratz M, Damman CJ, Hullarg M. Mechanisms linking the gut microbiome and glucose metabolism. *J Clin Endocrinol Metabol* 2016;101(4):1445–54.
- [54] Sahebkar A, Serban M-C, Ursoniu S, Banach M. Effect of curcuminoids on oxidative stress: a systematic review and meta-analysis of randomized controlled trials. *J Funct Foods* 2015;18:898–909.
- [55] Kim SH, Hyun SH, Choung SY. Anti-diabetic effect of cinnamon extract on blood glucose in db/db mice. *J Ethnopharmacol* 2006;104(1–2):119–23.
- [56] Adams AA, Katepalli MP, Kohler K, Reedy SE, Stilz JP, Vick MM, et al. Effect of body condition, body weight and adiposity on inflammatory cytokine responses in old horses. *Vet Immunol Immunopathol* 2009;127(3–4):286–94.
- [57] Anderson RA, Zhan Z, Luo R, Guo X, Guo Q, Zhou J, et al. Cinnamon extract lowers glucose, insulin and cholesterol in people with elevated serum glucose. *J Tradit Complementary Med* 2016;6(4):332–6.